Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation - Classification and comparison with crystallization tendency from undercooled melts

Journal of Pharmaceutical Sciences

Volumn 99, Issue 9, 2010, Pages 3826-3838

  Van Eerdenbrugh, Bernard ^a   Baird, Jared A ^a   Taylor, Lynne S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Amorphous state; Classification; Crystallization; Physical stability; Solvent evaporation; Spin coating

Indexed keywords

ALCOHOL; DICHLOROMETHANE; SOLVENT;

ARTICLE; COOLING; CRYSTALLIZATION; EVAPORATION; MELTING POINT; MICROSCOPY; PHYSICAL CHEMISTRY; POLARIZATION; SOLUBILITY;

EID: 77955234073     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22214     Document Type: Article

References (33)

1. Baird JA, Van Eerdenbrugh B, Taylor LS. 2010. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci DOI: 10.1002/jps.22197.
2. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification - The correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm Res 12:413-420.
3. Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785-796.
4. Brewster ME, Loftsson T. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645-666.
5. Millard JW, Alvarez-Núňez FA, Yalkowsky SH. 2002. Solubilization by cosolvents - Establishing useful constants for the log-linear model. Int J Pharm 245:153-166.
6. Stella VJ, Nti-Addae KW. 2007. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 59:677-694.
7. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60.
8. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
9. Ambike AA, Mahadik KR, Paradkar A. 2004. Stability study of amorphous valdecoxib. Int J Pharm 282:151-162.
10. Gupta P, Kakumanu VK, Bansal AK. 2004. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res 21:1762-1769.
11. Van Eerdenbrugh B, Van Speybroeck M, Mols R, Houthoofd K, Martens JA, Froyen L, Van Humbeeck J, Augustijns P, Van den Mooter G. 2009. Itraconazole/TPGS/Aerosil® 200 solid dispersions: Characterization, physical stability and in vivo performance. Eur J Pharm Sci 38:270-278.
12. van Drooge DJ, Hinrichs WLJ, Frijlink HW. 2004. Anomalous dissolution behavior of tablets prepared from sugar glass-based solid dispersions. J Control Release 97:441-452.
13. SavolainenM, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C, Yliruusi J. 2009. Better understanding of dissolution behaviour of amorphous drugs by in-situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm 71:71-79.
14. Alonzo DE, Zhang GGZ, Zhou D, Gao Y, Taylor LS. 2010. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res 27:608-618.
15. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97:1329-1349.
16. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
17. Willart JF, Descamps M. 2008. Solid state amorphization of pharmaceuticals. Mol Pharm 5:905-920.
18. Ravis WR, Chen CY. 1981. Dissolution, stability, and absorption characteristics of dicumarol in polyethylene glycol-4000 solid dispersions. J Pharm Sci 70:1353-1357.
19. Six K, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2004. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci 93:124-131. (Pubitemid 38081820)
20. Marsac PJ, Konno H, Taylor LS. 2006. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res 23:2306-2316.
21. Greaser KA, Patterson JE, Zeitler JA, Gorond KC, Rades T. 2009. Correlating thermodynamic and kinetic parameters with amorphous stability. Eur J Pharm Sci 37:492-498.
22. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 23:2417-2426.
23. Bornside DE, Macosko CW, Scriven LE. 1987. On the modeling of spin coating. J Imaging Technol 13:122-130.
24. Hendriksen BA, Grant DJW. 1995. The effect of structurally related substances on the nucleation kinetics of paracetamol (acetaminophen). J Cryst Growth 156:252-260.
25. Lechuga-Ballesteros D, Rodríguez-Hornedo N. 1995. The influence of additives on the growth-kinetics and mechanism of L-alanine crystals. Int J Pharm 115:139-149.
26. Davey RJ, Blagden N, Potts GD, Docherty R. 1997. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J Am Chem Soc 119:1767-1772. (Pubitemid 27145524)
27. Hendriksen BA, Grant DJW, Meenan P, Green DA. 1998. Crystallisation of paracetamol (acetaminophen) in the presence of structurally related substances. J Cryst Growth 183:629-640.
28. Weissbuch I, Lahav M, Leiserowitz L. 2003. Toward stereochemical control, monitoring, and understanding of crystal nucleation. Cryst Growth Des 3:125-150. (Pubitemid 37138718)
29. Anwar J, Boateng PK, Tamaki R, Odedra S. 2009. Mode of action and design rules for additives that modulate crystal nucleation. Angew Chem Int Ed 48:1596-1600.
30. Khoshkhoo S, Anwar J. 1993. Crystallization of polymorphs: The effect of solvent. J Phys D Appl Phys 26:B90-B93.
31. Yu L, Reutzel-Edens SM, Mitchell CA. 2000. Crystallization and polymorphism of conformationally flexible molecules: Problems, patterns, and strategies. Org Process Res Dev 4:396-402.
32. Turnbull D, Fisher JC. 1949. Rate of nucleation in condensed systems. J Chem Phys 17:71-73.
33. James PF. 1985. Kinetics of crystal nucleation in silicate-glasses. J Non-Crystalline Solids 73:517-540.